Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Women generally handle heart enlargement better than men, but it's riskier for them if it occurs; hormones like estrogen offer some protection.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.

The conclusion is that certain surgeries can help people with gender dysphoria look more like their true gender and feel better.

In Japan, sex reassignment surgery for gender identity disorder faces challenges and needs better medical support and education.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Most insurance companies do not cover extra gender-affirming surgeries, with coverage being low and inconsistent.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

Women's hair grows faster and thicker than men's, but hair growth slows for both genders with pattern hair loss.

Transgender youth have more sleep disorders, but gender-affirming therapy may help reduce them.

Men and premenopausal women in Korea show different patterns in iron and vitamin D levels, with no clear pattern for postmenopausal women.

Gender differences affect allergy prevalence, severity, and response to environmental toxins, with women often more affected than men.

AGA treatments like minoxidil and LLLLT are safe and effective for gender minority patients.

Women pay more for the same 5% minoxidil foam than men, but prices for liquid solutions are similar.

Men are more likely to have larger basal cell carcinomas and squamous cell carcinomas, while women have more superficial basal cell carcinomas and tumors on their legs and central face.

Transgender and nonbinary individuals experience hair loss, with transmen on testosterone seeing more severe hair loss, while feminizing hormones may stabilize hair loss in transwomen.

AGA risk factors include age, smoking, hypertension for men, and age, dyslipidemia for women; lifestyle changes may help prevention.

Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.

Women who lost hair from childhood head radiation are more likely to face mental health issues than men.

Iron levels are linked to insulin resistance in men and postmenopausal women, but not in premenopausal women.

A genetic variant in the androgen receptor gene increases heart disease risk in women but not in men.

Women's facial moisturizers cost more per ounce than men's.

Gender affects wool traits in sheep, with males and females showing differences in skin proteins related to wool growth.

Hormone therapy greatly improves the quality of life for adults seeking gender reaffirmation, but more research is needed in India.

Feminizing hormone therapy increases kidney filtration rate.

Gender-affirming hormone therapy affects metabolism differently based on treatment type.

Topical minoxidil helps transgender individuals assigned female at birth grow more facial hair.

Hormone therapy in transgender and gender diverse individuals affects hair loss differently than in cisgender individuals.

Gender-affirming hormone therapy improves physical performance in trans men to the level of cisgender men, while in trans women, it increases fat mass and decreases muscle mass, with no advantage in physical performance after 2 years.